And oral soluble guanylate cyclase stimulator.
It enhances the cyclic guanosine monophosphate (GMP) pathway by directly stimulating soluble guanylate cyclase through a binding site independent of nitric oxide, and it sensitize is soluble granulate cyclase to endogenous nitrogen oxide by stabilizing nitric oxide binding to the binding site.
In heart failure with preserved ejection fraction a deficiency of cyclic guanosine monophosphate may be involved because it modulates the central and peripheral pathophysiologic pathways.
Vericigluat Is a oral soluble guanylate cyclase stimulator, that directly generates cyclic guanosine monophosphate and restores the sensitivity of soluble guanylate cyclase to endogenous nitrous oxide.
Indicated to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
Reduces NT-proBNP in patients with heart failure and reduced ejection fraction.
Among patients with high risk heart failure, the incidence of death from cardiovascular causes or hospitalization for HF is lower among those who receive this drug than among those who receive placebo. (Armstrong PW).
In a study of patients with heart failure and reduced ejection fraction there was no significant benefit with respect to primary outcome but with higher doses it was associated with the grading reduction in levels of NT-proBNP.
Among patients with heart failure and preserved ejection fraction and recent decompensation, treatment with vericiglut compared with placebo did not improve the physical limitations score.
It is not induce tolerance with long-term administration.
Contra indicated in pregnancy.